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Weight gain is one of the major drawbacks associated with the pharmacological treatment of schizophrenia. Existing strategies for
the prevention and treatment of obesity amongst these patients are disappointing. Switching the current antipsychotic to another
t h a tm a yf a v o r a b l ya ﬀect weight is not yet fully established in the psychiatric literature. This meta-analysis focused on switching to
aripiprazole as it has a pharmacological and clinical proﬁle that may result in an improved weight control. Nine publications from
seven countries worldwide were analyzed. These encompassed 784 schizophrenia and schizoaﬀective patients, 473 (60%) men and
311 (40%) women, mean age 39.4 ± 7.0 years. The major signiﬁcant ﬁnding was a mean weight reduction by −2.55 ± 1.5kgs
following the switch to aripiprazole (P<. 001). Switching to an antipsychotic with a lower propensity to induce weight gain needs
be explored as a strategy. Our analysis suggests aripiprazole as a candidate for such a treatment strategy.
1.Introduction
Excessive bodyweight gain is not a new clinical observation
amongstpatientstreatedwithantipsychoticsandwasalready
reported during the 1950’s as an adverse eﬀect of typical
antipsychotic drug treatment. Hence, one of the major
diﬃculties facing patients suﬀering from schizophrenia and
health care professionals is obesity. In comparison to the
general population, these patients have higher rates of mor-
bidity and mortality, which are thought to be due, in part, to
increasedratesofobesity.Thisproblemhasbeenexacerbated
more recently with the introduction and increased use of
second generation antipsychotics (SGA), several of which
are associated with the risk of weight gain and metabolic
disturbance [1] .T h em a gn i t u d eo fbo d y w e i gh tga i nr e p o rt e d
in the largest naturalistic treatment studies (the CATIE
study) of patients treated by SGAs with bodyweight gain of
>7%comparedwithbaselinewasintherangeof12%to30%
[2, 3].
In many obese patients suﬀering from schizophrenia,
treatment based on only lifestyle interventions is limited
by the core symptomatology of the disease, medication
side eﬀects, and patient’s nonadherence and thus may not
result in desirable weight loss. Nevertheless, antipsychotic-
induced weight gain is an important modiﬁable parameter
in the high rates of obesity in this population. The need
for an eﬀective complementary drug treatment would be
advantageous speciﬁcally for this large group of vulnerable
patients.
The Schizophrenia Patient Outcomes Research Team
(PORT) psychopharmacological treatment recommenda-
tions provide a wide-ranging summary of current evidence-
based pharmacological treatment practices. The latest report
of the PORT group was recently published, and the phar-
macological prevention and treatment of antipsychotic-
associated weight gain in schizophrenia were speciﬁcally
addressed [4]. The PORT approach for obesity associated
with antipsychotic medications is important in treatment
and prevention. Three pharmacological strategies have been
evaluated by this group: (1) switching current antipsychotic
to an antipsychotic with a lower propensity for weight gain,
(2) employing a medication to prevent weight gain, and (3)2 Journal of Obesity
addition of a medication to patients who have gained weight
during therapy in order to promote weight loss. Regrettably,
there is currently insuﬃcient evidence to recommend any of
these strategies.
The equivocal recommendations of the PORT group
have been challenged by researchers and clinicians who have
focused on “switching” antipsychotic medications as a viable
strategy to induce weight loss. Development of obesity in
patients suﬀering from schizophrenia who were stabilized
on SGA has been the framework by these researchers. Risks
and beneﬁts of staying on current treatment versus switching
to another agent and switching strategies were evaluated,
concluding that switching to another antipsychotic with
more favorable side eﬀects is called for if other weight-loss
strategies fail [3]. However, there is little evidence to support
which is the best switching strategy [5]. There are several
SGAs that may be feasible candidates for switching strategy.
These may include ziprasidone, amisulpride, paliperidone,
andaripiprazole[6].Althoughthedebateaboutthepotential
relationship between aripiprazole therapy and the risk of
weightgainisnotyetresolved,ithasbeenalsostatedthatthis
speciﬁc aspect of the safety proﬁle of aripiprazole assumed
on the basis of its unusual pharmacological characteristics
mayresultinadecreasedadverseimpactonweightthatoften
complicates management for a large number of patients suf-
fering from schizophrenia treated chronically with antipsy-
chotics [7, 8]. Clinical characteristics of aripiprazole in
comparison to other SGAs have been recently evaluated
by the Cochrane Collaboration. The authors observed that
aripiprazole was associated with fewer side eﬀects such as
weight gain, cholesterol increase, sedation, and prolactin-
associated side eﬀects, concluding that aripiprazole may be
more tolerable in terms of metabolic eﬀectsand sedation [9].
T h ep r i m a r yo b j e c t i v eo ft h i sm e t a - a n a l y s i sw a st o
examine the eﬃcacy of switching to aripiprazole as a strategy
for achieving weight loss in schizophrenia patients currently
using other antipsychotics.
2.MaterialsandMethods
2.1. Study Selection and Data Collection. At the beginning of
this project, we drafted a study protocol. For our analysis,
we included all trials in which patients suﬀering from
schizophrenia or schizoaﬀective disorder (DSM-IV criteria)
treated with any antipsychotic were switched to aripiprazole
monotherapy in acute-phase or maintenance treatment. We
excluded placebo groups where present.
The authors independently reviewed references and
abstracts retrieved by the search, assessed the completeness
of data abstraction, and conﬁrmed quality rating. We used
a structured data abstraction form to ensure consistency
of appraisal for each study. Investigators were contacted
and asked to provide data to supplement the incomplete
reporting of the original articles [10].
2.2. Outcome Measures. We deﬁned mean change from
baseline weight (and standard deviation) as the primary
eﬃcacy outcome measure in the present analysis.
Studies were included only if mean change in weight was
reported as well as the following variables: (a) design: indus-
try support, sample size, previous antipsychotic treatment,
aripiprazole dose, and treatment duration. (b) demographic:
age, gender, and diagnosis.
2.3. PubMed. A PubMed literature search (last search April
2010) was performed to identify all original research articles
using aripiprazole to determine weight change in adult
patients.
The search terms were (“aripiprazole” or “abilify”),
(“schizophrenia”or“schizoaﬀectivedisorder”)and(“switch”,
“weight”, “metabolic”, “BMI”, or “obesity”) in the abstract,
title, or index terms.
2.4. Additional Electronic Searches. Studies were searched
for using the following search strategy: Diagnosis =
Schizophrenia∗ or Schizoaﬀective∗ and Intervention = arip-
iprazole. References were searched using the same search
strategy with the addition of Free-Text = weight. The
researchers conducted searches on the MEDLINE and Psych-
Info and checked various meta-analyses and review articles
on the 8th of April 2010.
Searching other resources includes the following.
(1) Hand searches. We also searched the ongoing trial
register http://clinicaltrials.gov/ in the USA.
(2) Personal communication. Experts in this ﬁeld were
asked if theyknew of anystudy that met the inclusion
criteria of this review.
(3) Reference checking. Reference lists of the included
studies, previous systematic reviews, and major
textbooks of schizophrenia written in English were
checked for published reports and citations of
unpublished research
2.5. Data Extraction and Management. Both authors extract-
ed data from the included studies. Again, any disagreement
was discussed, and decisions were documented. Retrieved
data was rated dichotomously by each author as either
“suﬃcient” or “inadequate”. Only studies for which both
authors’ ratings were “suﬃcient” were included in the
present analysis.
If necessary, we contacted the authors of the studies for
clariﬁcation. We extracted the following data:
(i) participant characteristics,
(ii) intervention details,
(iii) outcome measures of interest from the included
studies.
2.6. Data Synthesis and Statistical Analysis. Our primary
method for the assessment of weight reduction was through
pooled estimates using ﬁxed-eﬀects meta-analyses method-
ology. This allowedtheintegration of information toprovide
an estimate with a 95% conﬁdence interval (CI). The results
also allow us to make probabilistic statements about theJournal of Obesity 3
eﬀect size; that is, we are able to answer the following
question: “Given the observed data, what is the probability
that switching treatment to aripiprazole will induce weight
loss?”
Analyses were performed on those antipsychotic med-
ications with published studies that were completed in
the period from 2003 to 2010. Also, pooled results were
estimatedbysubgroupsofdiagnosis,samplesize,andgender.
Data analysis was carried out with the use of the
Statistical Analysis System software, SAS Institute, version
9.1.3 from 2007.
3. Results andDiscussion
3.1. Results. The literature search yielded 47 articles, of
which 11 manuscripts fulﬁlled the inclusion criteria for the
present meta-analysis. These studies spanned the period
from 2003 to 2010. Taken altogether, the cumulative sample
size included 786 patients [11–21]. There were also 2 case
reports [13, 14] which were excluded from the ﬁnal analysis.
Characteristics of the ﬁnal 784 analyzed participants are
presented in Table 1.
The sample analyzed was composed mainly of adult
males suﬀering from schizophrenia. Mean age for the sample
was 39.4 ± 7.0 years (range: 30 to 54); there were 473
(60%) men and 311 (40%) women, of whom 644 (82%)
were diagnosed as suﬀering from schizophrenia, and 140
(18%) were suﬀering from schizoaﬀective disorder. Half of
the studies were conducted in the USA (5/9), two in Korea,
one each in the Netherlands, Japan, and Eastern Europe. It
should be noted that one of the studies was an international
collaboration between USA and East European researchers.
Thus, 422 (54%) of patients were of Caucasian ethnicity, and
148 (19%) were Korean.
Antipsychotic medications resulting in weight gain for
which the later switch to aripiprazole was undertaken were
distributed as follows: olanzapine 352 (46%), risperidone
226 (30%), typical—ﬁrst generation 168 (22%), sulpiride
17 (3%), clozapine 11 (1%), and quetiapine 10 (1%). Mean
weight for the sample prior to switching to aripirazole was
83.8 ± 15.4kgs (range: 63 to 104); mean aripirazole dose
following the switch was 20.2 ± 5.0mgs/daily (range: 15 to
30), and mean duration of aripirazole treatment was 26.2 ±
16.9 weeks (range: 8 to 56). In all studies herein analyzed, a
minimal reduction in weight of 1.2kgs was reported. In the
four largest studies included [11, 12, 18, 19], the reduction in
weight was statistically signiﬁcant, P<. 001. It is of interest
to note that the weight reduction observed in the two case
reports (10.5 and 16.8kgs) was extremely higher than that
reported in the large-scale studies [13, 14].
Body mass index (BMI) was reported only in 2 studies,
and thus we were unable to analyse the signiﬁcance in
it’s change. In one study [11], reduction in BMI following
aripiprazole treatment was −1.3, and in the second study
[16]i tw a s−0.5.
Following the switch to aripirazole, a reduction in weight
of7%ormorewasobservedin52/484patients(10.7%)while
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Figure 1: Mean reduction in weight (kgs) across analyzed studies.
an increase of 7% or more in weight was observed in 22/484
(4.5%); this was highly statistically signiﬁcant, P<. 0004.
Correlations computed for weight reduction and gender,
age, ethnicity, or aripiprazole dose did not reach statistical
signiﬁcance. Duration of aripiprazole treatment was neg-
atively correlated with the weight change (longer time =
greater weight loss) not reaching statistical signiﬁcance (R2
= −0.48, P = .085).
The major signiﬁcant ﬁndings of the present analysis
were the following:
(i) mean weight reduction by −2.55 ± 1.5kgs 95% CI:
−3.7t o−1.4( r a n g e :−1.2t o−5.3) following the
switch to aripiprazole was statistically signiﬁcant, P<
.001. See Figure 1.
(ii) mean weight reduction was statistically greater for
patients diagnosed as suﬀering from schizophrenia
(−2.67kgs) when compared to mean reduction
in patients suﬀering from schizoaﬀective disorder
(−2.18kgs), P<. 022.
(iii) the most signiﬁcant mean weight reduction
(−2.74kgs) was noted in patients who were
exposed to olanzapine prior to switching treatment
to aripiprazole, P<. 001.
3.2. Discussion. The introduction of the SGAs has brought
to the forefront the awareness that antipsychotic treatment
is associated with an increase in weight, adversely aﬀecting
cardiac and metabolic risks. However, not all antipsychotics
are thought to contribute to the same degree, and the
possibility of switching antipsychotic medications to reduce
the induced weight gain has been intriguing [22].
Several reports on studies in which already overweight,
antipsychotic-treated patients were allocated to switch to
aripiprazole have been published. Aripiprazole treatment
wasthenassociatedwithsigniﬁcantimprovementsinweight.
However, to the best of our knowledge, no meta-analysis
encompassing all switching studies has been carried out to
date. The strength of weight reduction eﬀect was deemed4 Journal of Obesity
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clinically meaningful in the present analysis and is consistent
with previous research in weight-unselected patients [23].
Our results support the suggestion that switching might be
considered for any antipsychotic-treated patients who had
gained weight. More so, for those possessing pre-existing
cardiac and metabolic risk factors, an early switch to a more
metabolically neutral antipsychotic such as aripiprazole
might serve best.
In general, switching studies are carried out to evaluate
whether switching results in further symptom improvement
[24] .T h eB E T Aa n dE U - B E T As t u d i e s[ 25], as well as other
switching studies [12, 16, 24], have focused mainly on the
degree of clinical improvement, tolerability, and safety pro-
ﬁles. However, data from these studies was herein analyzed
to determine whether weight reduction may be achieved,
as clinicians who switch patients from one antipsychotic
agent to another are often concerned about the potential
for reducing this serious side eﬀect. Nevertheless, some
patients gain weight when treatment with an antipsychotic
is switched to aripiprazole. A clinically meaningful change
in weight is usually deﬁned as a change greater than 7%
of body weight before an intervention [26]. In the Kim
et al. naturalistic switch study [27], the authors reported
that the rate of patients switched to aripiprazole who had
gained weight was lower than that of patients continuing
standard-of-care antipsychotics. In the present analysis, the
rate of patients who had lost more than 7% of their weight
following the switch to aripiprazole was more than twice that
of patients who had gained more than 7% of their weight
prior to the switch.
3.3. Limitations. Some of the analyzed studies lacked data as
to BMI and to the rates of the 7% change in weight. There
were two single cases that were statistically “outliers” in the
reported weight reduction and were thus excluded from the
ﬁnal analysis. Age ranges limit generalization of our ﬁndings
to adolescents or the elderly. Finally, all of the studies with
the largest sample size were industrially supported.
4. Conclusions
Patients taking antipsychotic medications for psychiatric
disorders have also many risk factors for medical comorbidi-
ties. There is a pressing need for eﬀective interventions to
address problems related to the additional iatrogenic burden
from weight gain caused by antipsychotic medications. For
patients suﬀering from schizophrenia, discontinuation of
antipsychoticmedicationisnotadvisable,andthusswitching
to an antipsychotic with a lower propensity to induce weight
gain needs be explored as a strategy. Our analysis suggests, in
accord with previous ﬁndings [28], that aripiprazole could
be useful for patients treated with other antipsychotics who
show signiﬁcant weight gain, a well-established side eﬀect of
many antipsychotics.
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